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Summary
Background: Ventilator-associated pneumonia (VAP) is a leading cause of death in hospitalized
patients, but there has been no systematic analysis of the incidence, microbiology, and outcome
of VAP in developing countries or of the interventions most applicable in that setting.
Methods: We reviewed MEDLINE (January 1966—April 2007) and bibliographies of the retrieved
articles for all observational or interventional studies that examined the incidence, microbiology,
outcome, and prevention of VAP in ventilated adults in developing countries. We evaluated the
rates of VAP using the National Healthcare Safety Network (NHSN) definitions and the impact of
VAP on the intensive care unit (ICU) length of stay (LOS) and mortality, and the impact of
interventions used to reduce VAP rates.
Results: The rates of VAP varied from 10 to 41.7 per 1000 ventilator-days and were generally
higher than NHSN benchmark rates. Gram-negative bacilli were the most common pathogens
(41—92%), followed by Gram-positive cocci (6—58%). VAP was associated with a crude mortality
that ranged from 16% to 94% and with increased ICU LOS. Only a small number of VAP intervention
studies were performed; these found that staff education programs, implementation of hand
hygiene, and VAP prevention practice guidelines, and/or implementation of sedation protocol
were associated with a significant reduction in VAP rates. Only one interventional study was a
randomized controlled trial comparing two technologies, the rest were sequential observational.
This study compared a heat and moisture exchanger (HME) to a heated humidifying system (HHS)
and found no difference in VAP rates.
Conclusions: Based on the existing literature, the rate of VAP in developing countries is higher
than NHSN benchmark rates and is associated with a significant impact on patient outcome. Only a
few studies reported successful interventions to reduce VAP. There is a clear need for additional* Corresponding author. Tel.: +966 1 2520088x18855/18877; fax: +966 1 2520088x18880.
E-mail address: arabi@ngha.med.sa (Y. Arabi).
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epidemiologic studies to better understand the scope of the problem. Additionally, more work needs
to be done on strategies to prevent VAP, probably with emphasis on practical, low-cost, low
technology, easily implemented measures.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Ventilator-associated pneumonia (VAP) is a leading cause
of morbidity and mortality in intensive care unit (ICU)
patients.1—4 Several countries have reported mortality rates
ranging from 24% to 76%.5,6 As a result, prevention of VAP has
become a focus of patient safety initiatives. Prevention of
nosocomial infections, including VAP, was identified as a
priority area for national action by the Institute of Medicine.7
Similarly, the Joint Commission on Accreditation of Health-
care Organizations (JCAHO) has included prevention of
healthcare-associated infections, including VAP, in its 2006
National Patient Safety Goals and recommended to manage
as sentinel events all identified cases of unanticipated death
or major permanent loss of function associated with a health-
care-associated infection, including VAP.8 The prevention of
VAP is a component of the Surgical Care Improvement Project
(SCIP).9 VAP prevention is one of the six components of the
‘100K Lives’ campaign and a key component of the ‘Protect-
ing 5 Million Lives from Harm’ campaign launched by the
Institute for Healthcare Improvement (IHI).10,11 The IHI has
promoted VAP prevention and safety of patients on mechan-
ical ventilation by implementing a set of interventions known
as the ‘ventilator bundle’.12 This bundle includes four com-
ponents: (1) elevation of the head of the bed to between 30
and 45 degrees, (2) daily interruption of sedation and daily
assessment of readiness to extubate, (3) peptic ulcer disease
prophylaxis, and (4) deep vein thrombosis prophylaxis.
In contrast, VAP has received little attention in developing
countries until recently.13 The purpose of this review was to
evaluate the incidence, microbiology, and outcome of VAP in
developing countries and to identify if any of the preventive
interventions described before have been applied to reduce
VAP rates in these regions of the world.
Methods
Search strategy
We conducted a MEDLINE search including all publications
from January 1966 to April 2007, to identify all studies that
investigated VAP in developing countries as identified by the
World Bank.14 We used a combination of MeSH terms (‘Ven-
tilators, Mechanical’ [MeSH] OR ‘Respiration, Artificial’
[MeSH] OR ‘Hospitals’ [MeSH]) AND (‘Pneumonia’ [MeSH]
OR ‘Infection’ [MeSH] OR ‘Respiratory Tract Infections’
[MeSH]) AND ‘Developing Countries’ [MeSH]. Reference lists
of key reviews were also searched for additional studies. We
also conducted a manual search using the following terms:
‘nosocomial’, ‘ventilator’, ‘pneumonia’, ‘developing coun-
tries’, and ‘infection’. Citations were limited to in vivo
human studies, full articles, and those publications in the
English language. Neither unpublished data nor abstracts
were included.Inclusion criteria
We included all studies (observational and interventional,
prospective and retrospective) from developing countries
that: (1) used the US Centers for Disease Control and Pre-
vention (CDC) National Healthcare Safety Network (NHSN)
definitions15 (previously known as the National Nosocomial
Infections Surveillance (NNIS)), (2) examined mechanically
ventilated adult patients in the ICU, and (3) examined the
epidemiology, microbiology, outcome, or prevention of VAP.
In the case of multiple studies addressing the same subject
and coming from the same hospital of the same country, we
used only the latest data.
Study identification
The titles and abstracts generated by the initial search were
reviewed by two authors (YA and NS) to identify potential
studies that met the inclusion criteria. In all instances where
the abstract title indicated that the article might be rele-
vant, the full article was obtained. The same two authors
reviewed the full text of these articles and applied the
inclusion criteria independently. We resolved differences
by discussion and consultation with a third author (ZM) in
the event that agreement could not be reached. The
reviewers were not blinded to the authors or the institutions
where the studies were conducted.
Data abstraction and outcome measures
For each study, the following data were abstracted: country
of study, study design, type of population, and number of
patients. We evaluated the following outcome measures:1. The VAP rate expressed as episodes per 1000 ventilator-
days as per the CDC NHSN definitions.1,152. The microbiology of VAP.3. The impact of VAP on duration of mechanical ventilation,
ICU length of stay (LOS), or mortality.4. For intervention studies, we documented the type of
intervention and impact on VAP rate or surrogate markers
for VAP prevention.Data analysis
Descriptive statistics were used as appropriate. Comparative
statistics are presented as reported by authors.
Results
Epidemiology
We identified 22 studies that reported VAP rate using the CDC
NHSN definition (Table 1)16—35; single country studies were
Table 1 Ventilator-associated pneumonia (VAP) rates in developing countries
Study [Ref.] Year Country VAP ratea Type of ICU
Elatrous16 1996 Tunisia 40 Medical
Velasco17 1997 Brazil 41.7 Oncology ICU
Barsic18 1999 Croatia 28—37 NA
Khuri-Bulos 19 1999 Jordan 19.1 Medical-surgical
Memish20 2000 Saudi Arabia 16.8 Medical-surgical
Memish21 2001 Saudi Arabia HME 13.3 Medical-surgical
HHS 15.7
Simsek22 2001 Turkey 16.4 Cardiac-surgical
Jamulitrat23 2002 Thailand 32 NA
Kanafani 24 2003 Lebanon 30 Medical-surgical
Thongpiyapoom25 2004 Thailand 10.8 Medical-surgical
Jamulitrat26 2004 Thailand 10.8 Medical-surgical
Noor27 2005 Pakistan 26 Medical surgical
Moreno28 2006 Colombia 10 Medical-surgical
Inan29 2006 Turkey 20.8 Medical-surgical
Ertugrul 30 2006 Turkey 28.7 Surgical
Ramirez Barba31 2006 Mexico 21.8 Medical-surgical
Rosenthal 32 2006 Argentina 35.5 Medical-surgical and CCU
Rosenthal 33 2006 Eight countries b 24.1 (10—52.7) Medical-surgical, CCU
Jaimes34 2007 Colombia 29 3 ICUs: surgical/trauma,
medical, cardiovascular
Leblebicioglu35 2007 Turkey 26.5 13 ICUs, 12 hospitals
ICU, intensive care unit; NA, not available; HME, heat and moisture exchanger; HHS, heated humidifying system; CCU, coronary care unit.
a Episodes per 1000 ventilator-days.
b The eight countries were: Argentina, Brazil, Colombia, India, Mexico, Morocco, Peru, and Turkey.
Figure 1 Ventilator-associated pneumonia (VAP) rates in med-
ical-surgical intensive care units (ICUs) in several developing
countries. The solid line represents the pooled mean rate of VAP
from the US Centers for Disease Control and Prevention (CDC),
according to the National Healthcare Safety Network medical-
surgical ICUs and the shaded area represents the 25—75 percen-
tile rate.
Ventilator-associated pneumonia in developing countries 507most commonly from the Middle East (n = 10), followed by
South America (n = 5) then Southeast Asia (n = 3). There were
international studies that included developed and developing
countries but reported pooled mean and not individual coun-
try rates.6 The VAP rate (per 1000 ventilator-days) ranged
from as low as 10 per 1000 ventilator-days in Thailand25,26
and Colombia28 to a high of 41.7 per 1000 ventilator-days in a
study on oncology ICU patients from Brazil.17 Figure 1 shows
the VAP rates in medical-surgical ICUs compared with the
pooled mean rate and 25—75 percentile rates of VAP in the US
medical-surgical ICUs as per the CDC NHSN.15
Microbiology
The microbiology of VAP was reported in 22 studies (Table 2).
Gram-negative bacilli were responsible for the majority of
VAP episodes (41—92%). Overall, Pseudomonas aeruginosa
was the most common isolated Gram-negative organism
(9—52%),16,18,20—22,27—29,33,36—41 followed by Acinetobacter
spp (0—36%).24,25,30,42,43 Gram-positive cocci were responsi-
ble for 6—58% of the isolates. Candida spp accounted for
between 0 and 7% of VAP episodes, although not all studies
reported the percentage of Candida spp isolates.
Association of VAP and outcome
Fifteen studies examined mortality of patients with VAP in
developing countries, and five studies reported ICU LOS
(Table 3). The crude VAP mortality rate ranged from 16%
to 94% compared to 0.2% to 51% in non-VAP patients. ICU LOS
of VAP patients ranged from 8 to 24 days compared to 2.5 to13 days in non-VAP patients. Pawar et al. studied 25 VAP
patients in a cardiac-surgical ICU in India41 and found that
VAP was associated with increased ICU LOS by 10 days and
higher mortality than patients without VAP (16 vs. 0.2%;
p < 0.0002). Kanafani studied 70 patients admitted to a
medical-surgical ICU in Lebanon24 and found that ICU LOS
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508 Y. Arabi et al.increased from a mean of 11 days in patients without VAP to
24 days in patients with VAP)p = 0.013). The mortality was
39% for VAP patients vs. 30% for non-VAP patients, but the
difference was not statistically significant. A study by
Rosenthal from a medical-surgical ICU in Argentina reported
an attributable mortality of 35% and 10 attributable extra
days of hospitalization associated with VAP.44 Other studies
also found similar results.28,30,37—39
Intervention studies to prevent VAP in developing
countries
Eight studies described VAP prevention studies21,32,45—50 and
are summarized in Table 4. The study design of all was of
pre-/post-intervention comparison except for one study,
which was a randomized controlled trial. The non-rando-
mized design reflects that these studies were examining non-
technologic infection control interventions, while the rando-
mized trial compared different similar and equivalent tech-
nologies. Berg et al. examined the effectiveness of specific
infection control interventions in a teaching hospital in
Guatemala City.45 After 3months of prospective surveillance,
the investigators implemented targeted interventions
including modification of respiratory tract care, an educa-
tional program focused on respiratory intervention, and
general interventions (i.e., aseptic techniques). As a result
of intervention, the frequency of hand washing increased
from 5% to 63% ( p < 0.001) and the VAP rate dropped from
113 to 40 per 1000 ventilator-days ( p = 0.001). Rosenthal
et al. monitored the compliance with hand hygiene during
routine patient care in two ICUs in Buenos Aires, Argentina,
before and during implementation of a hand hygiene educa-
tion, training, and performance feedback program. Compli-
ance improved from 23.1% to 64.5% ( p < 0.0001). During the
same period, VAP rates decreased from 47.6 to 27.9 per 1000
ventilator-days ( p < 0.001).48 Another study by the same
authors32 examined all adult patients who received mechan-
ical ventilation for at least 24 hours in four level III adult ICUs
in two Argentine hospitals. The VAP rate was determined
during a period of active surveillance without an infection
control program (phase 1) and was compared with the VAP
rate after implementation of an infection control program
that included educational and surveillance feedback compo-
nents (phase 2). The investigators found that the rates of VAP
were significantly lower in phase 2 than in phase 1 (51.28 vs.
35.50 episodes of VAP per 1000 ventilator-days, respectively,
p  0.003). Salahuddin et al. conducted a pre- and post-
intervention study in a university hospital in Pakistan to
assess whether an educational program focusing on preven-
tive practices for VAP could reduce the incidence. Evidence-
based guidelines for preventive practices (including practice
guidelines on hand hygiene, protective clothing, semi-
recumbent positioning, avoidance of gastric distention, the
use of non-invasive ventilation, proper levels of sedation,
and oral hygiene with chlorhexidine oral rinse) were devel-
oped and disseminated to the ICU staff. VAP infection rates
reduced by 51%, from 13.2 in the pre-intervention period to
6.5 per 1000 ventilator-days in the post-intervention period
(mean difference 6.7; 95% CI 2.9—10.4, p = 0.02).47 Khatib
et al. conducted a pre-/post-intervention study in Lebanon to
examine the effectiveness of warning labels attached per-
manently to the ventilators on improving the practice of hand
Table 3 The association of VAP with ICU LOS and mortality in developing countries
Study [Ref.] Year Country Type of ICU Total
No. of
patients
No. of
patients
with VAP
ICU LOS (days) Mortality (%)
VAP Non-VAP VAP Non-VAP
Elatrous16 1996 Tunisia Medical 73 28 20 13b 60% 51%
Stebbings37 1999 Singapore Medical 136 12 NA NA 73% 40%a
Simsek22 2001 Turkey Cardiac-surgical 1716 36 NA NA 30% NA
Memish21 2001 Saudi Arabia Medical-surgical 243 33 NA NA 28.8% NA
Mukhopadhyay39 2003 India Surgical 241 121 NA NA 94% 27%a
Pawar41 2003 India Cardiac-surgical 952 25 14 4a 16% 0.2%a
Kanafani 24 2003 Lebanon Medical-surgical 70 40 24 11a 39% 30%
Rosenthal 44 2003 Argentina Medical-surgical 213 32 22 12 71% 37%
Erbay38 2004 Turkey Medical-surgical 97b 37 8 2.5a 70% 35%a
Noor27 2005 Pakistan NA 250 70 NA NA 57% 32%
Sallam36 2005 Egypt Medical-surgical-
cardiac
400 11 NA NA 63% NA
Luna42 2006 Argentina NA 508 76 NA NA 53% NA
Moreno28 2006 Columbia Medical-surgical 2172 86 NA NA 35% 18%a
Ertugrul 30 2006 Turkey Surgical 100 28 NA NA 36% 26%
Rosenthal 33 2006 8 countries Medical-surgical-
cardiac
21 069 1277 NA NA 44.9% 17.1%
VAP, ventilator-associated pneumonia; ICU, intensive care unit; LOS, length of stay; NA, not available.
a Statistically significant ( p < 0.05).
b Case—control study (number of controls = 60).
Ventilator-associated pneumonia in developing countries 509washing and the use of gloves by respiratory care practi-
tioners in the ICU. After placing the ‘‘wash hands, use gloves’’
labels, the rates of hand washing and use of gloves were
significantly higher during the second period when labels
were attached to the ventilators, as compared to the ratesTable 4 Interventional studies aiming at VAP reduction in develop
Study/year
[Ref.]
Country Study design Intervention
Berg
(1995)45
Guatemala Pre-/post-
intervention
Targeted Intervention
and education
Khatib
(1999) 46
Lebanon Pre-/post-
intervention
Hand washing and
glove use
Memish
(2001)21
Saudi Arabia Prospective
randomized
comparative
Use of HME vs. HHS
Salahuddin
(2004) 47
Pakistan Pre-/post-
intervention
Staff education progr
Rosenthal
(2005) 48
Argentina Pre-/post-
intervention
Hand hygiene training
and feedback program
Danchaivijitr
(2005) 49
Thailand Pre-/post-
intervention
Educational program
VAP prevention
Rosenthal
(2006) 32
Argentina Pre-/post-
intervention
Hand hygiene, proper
handling of respirator
secretions/education
sessions
Arabi 50 Saudi Arabia Pre-/post-
intervention
Sedation protocol and
educational program
about sedation
VAP, ventilator-associated pneumonia; NA, not available; HME, heat andduring the first period: hand washing, 92% vs. 46% ( p < 0.05);
use of gloves, 92% vs. 43% ( p < 0.05). The study did not
examine the effect of this intervention on the VAP rate.46
Memish et al. conducted a prospective randomized study in a
tertiary care ICU in Saudi Arabia comparing the incidence ofing countries
Outcome
measurement
VAP rate p-Value
Control Intervention
s VAP rate per
1000 ventilator-days
113 40 0.001
VAP rate was not
reported but rather
compliance with hand
washing and gloves
NA NA
VAP rate per 1000
ventilator-days
15.7 13.3 0.73
am VAP rate per 1000
ventilator-days
13.2 6.5 0.02
VAP rate per 1000
ventilator-days
47.6 27.9 <0.001
on VAP rate per 100
patients
40.5 24 <0.001
y
al
VAP rate per 1000
ventilator-days
51.3 35.5 <0.001
VAP rate per 100
patients
28 11 0.002
moisture exchanger; HHS, heated humidifying system.
510 Y. Arabi et al.VAP using the heat and moisture exchanger (HME) vs. the
heated humidifying system (HHS).21 They found that there
was no significant difference in the incidence of VAP between
the two systems. In the same ICU in Saudi Arabia, Arabi et al.
conducted a prospective, four-pronged, observational study
describing a quality improvement initiative that employs two
types of controlled comparisons: a ‘before and after’ com-
parison related to intense education of ICU clinicians and
nurses about sedation and analgesia in the ICU, and a com-
parison of protocolized versus non-protocolized sedation
practice. Patients were assigned alternatively to receive
sedation by a goal-directed protocol using the Riker seda-
tion—agitation scale (SAS) or by standard practice. A multi-
faceted multidisciplinary educational program was initiated
including the use of point of use reminders, directed educa-
tional efforts, and opinion leaders. This included several
lectures and in-services and the routine availability of at
least one member of this group to answer questions. The
investigators demonstrated significant reductions in the use
of analgesics and sedatives after 3 months of implementing
the protocol. This was associated with a reduction in the VAP
rate from 28 to 11 per 100 patients ( p = 0.002).50
Discussion
Our review demonstrates great variability in the reported
incidence and mortality rates of VAP in different developing
countries. The VAP incidence ranged from 10 to 41.7 per 1000
ventilator-days. Furthermore, we found that only few pro-
spective prevention interventional studies were performed.
The VAP incidence ranged from 10 to 41.7 per 1000
ventilator-days in different developing countries. This varia-
tion is probably related to several factors, including differ-
ences in patient populations (medical, surgical, vs. combined
ICUs), differences in infection control and critical care prac-
tices, and variability in data collection methods as well as
variability in the definition of VAP. The VAP incidence was
lower in surgical ICUs compared to medical-surgical
ICUs.24,32,44 However, this finding is not universal, as some
medical-surgical ICUs had a low incidence rate.25,26,28 This
may be explained by variation in surveillance methods and
different infection control practices in different developing
countries.51 It is worth noting that these rates were from
developing countries that have surveillance programs and
thus have reasonable healthcare infrastructures. The VAP
rates may be even higher in countries that do not have such
facilities. In addition, lack of appropriate surveillance data
may make the application of infection control measures and
assessing their outcome very difficult.51
In comparison, the CDC NHSN hospitals report a mean VAP
rate in US medical-surgical ICUs of 3.6 per 1000 ventilator-
days, in neurosurgical ICUs of 7.0 per 1000 ventilator-days,
and in trauma ICUs of 10.2 per 1000 ventilator-days.15 A
multicenter study from 16 Canadian ICUs reported a mean
VAP rate of 14.8 per 1000 ventilator-days.52 In Europe,
reported VAP ranged from 9.4 per 1000 ventilator days in
France,53 24 per 1000 ventilator days in Germany,54 to 35 and
46 per 1000 ventilator days in Italy.55,56 Thus, even in the
developed countries, considerable inter-country variation
exists, but it appears that in several developing countries,
VAP rates are higher than the reported rates from the USA,
Canada, and some European countries.Data on microbiology of VAP in developing countries
showed that Gram-negative bacilli were the predominant
organisms. This is similar to findings reported in North Amer-
ican and European studies.5 Pooled data collected from 24
Western studies showed that Gram-negative bacilli repre-
sented 58%, Staphylococcus aureus 20%, and other Gram-
positive organisms 14%,5 of VAP pathogens.
Our results revealed that mortality associated with VAP is
high in developing countries. Several studies demonstrated
higher mortality in VAP patients compared to those without
VAP, although some studies did not find a statistically sig-
nificant difference in mortality between VAP and non-VAP
patients. These findings are consistent with the crude mor-
tality of VAP that has been reported in developed countries
to range from 24% to 76% and attributablemortality from20%
to 30%.5,57
Several studies have shown that simple, cost-effective
measures can result in significant reduction in the incidence
of VAP in developing countries. Simple measures, e.g., hand
washing, proper handling of respiratory tract secretions, and
the use of gloves by health workers can reduce VAP rates if
they are re-enforced by training and programs.58 In addition,
all these measures are readily available and can be imple-
mented at a low cost in countries with limited healthcare
resources.
Conclusion
This review has addressed the incidence, microbiology, and
outcome of VAP in developing countries. In these countries,
VAP is a serious problem that is associated with high mortality
rates and increase in ICU LOS, which may represent an addi-
tional burden on the scarce resources in developing countries.
Further studies are needed to investigate additional VAP pre-
vention intervention in these settings. This review illustrates
the need for wide-scale initiatives for VAP prevention in
developing countries similar to those in developed countries.
Acknowledgments
Wewould like to thankWilliam R. Jarvis, MD, Jason and Jarvis
Associates, South Carolina, USA for critically reviewing the
manuscript.
Conflict of interest: No conflict of interest to declare.
References
1. Horan TC, Emori TG. Definitions of key terms used in the NNIS
system. Am J Infect Control 1997;25(2):112—6.
2. Bercault N, Boulain T. Mortality rate attributable to ventilator-
associated nosocomial pneumonia in an adult intensive care unit:
a prospective case—control study. Crit Care Med 2001;29(12):
2303—9.
3. van Nieuwenhoven CA, Bergmans DC, Bonten MJ. Ventilator-
associated pneumonia: risk factors and patient mortality. Hosp
Med 1999;60(8):558—63.
4. Leroy O, Sanders V, Girardie P, Devos P, Yazdanpanah Y, Georges
H, et al. Mortality due to ventilator-associated pneumonia:
impact of medical versus surgical ICU admittance status. J Crit
Care 2001;16(3):90—7.
5. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J
Respir Crit Care Med 2002;165(7):867—903.
Ventilator-associated pneumonia in developing countries 5116. Tejerina E, Frutos-Vivar F, Restrepo MI, Anzueto A, Abroug F,
Palizas F, et al. Incidence, risk factors, and outcome of venti-
lator-associated pneumonia. J Crit Care 2006;21(1):56—65.
7. Adams K, Corrigan JM, editors. Priority areas for national
action: transforming health care quality. Washington, DC:
The National Academies Press; 2003.
8. The Joint Commission. 2006 Disease-specific care national patient
safety goals. Available at: http://www.jointcommission.org/Gen
eralPublic/NPSG/06_npsg_dsc.htm (accessed 2006).
9. SCIP project information. Available at: http://www.medqic.
org/scip/ (accessed 2007).
10. Institute for Healthcare Improvement: 100,000 Lives Campaign.
Available at: http://www.ihi.org/IHI/Programs/Campaign/
100kLivesCampaignSuccessStories.htm (accessed 2007).
11. Institute for Healthcare Improvement: Protecting 5 Million Lives
from Harm. Available at: http://www.ihi.org/IHI/Programs/
Campaign/Campaign.htm?TabId=1 (accessed 2007).
12. Resar R, Pronovost P, Haraden C, Simmonds T, Rainey T, Nolan T.
Using a bundle approach to improve ventilator care processes
and reduce ventilator-associated pneumonia. Jt Comm J Qual
Patient Saf 2005;31(5):243—8.
13. Hasan R, Babar SI. Nosocomial and ventilator-associated pneu-
monias: developing country perspective. Curr Opin Pulm Med
2002;8:188—94.
14. The World Bank, Countries & Regions. http://web.worldbank.
org/WBSITE/EXTERNAL/COUNTRIES/0,,pagePK:180619theSite
PK:136917,00.html (accessed May 2008).
15. Edwards JR, Peterson KD, Andrus ML, Tolson JS, Goulding JS,
Dudeck MA, et al. National Healthcare Safety Network, (NHSN)
report, data summary for 2006, issued June 2007. Am J Infect
Control 2007;35(5):290—301.
16. Elatrous S. Incidence and risk factors of ventilator-associated
pneumonia: a one-year prospective survey. Clin Intensive Care
1996;7:176—281.
17. Velasco E, Thuler LC, Martins CA, Dias LM, Goncalves VM. Noso-
comial infections in an oncology intensive care unit. Am J Infect
Control 1997;25(6):458—62.
18. Barsic B, Beus I, Marton E, Himbele J, Klinar I. Nosocomial
infections in critically ill infectious disease patients: results of
a 7-year focal surveillance. Infection 1999;27(1):16—22.
19. Khuri-Bulos NA, Shennak M, Agabi S, Saleh S, Al Rawashdeh S, Al
Ghanem S, et al. Nosocomial infections in the intensive care
units at a university hospital in a developing country: comparison
with National Nosocomial Infections Surveillance intensive care
unit rates. Am J Infect Control 1999;27(6):547—52.
20. Memish ZA, Cunningham G, Oni GA, Djazmati W. The incidence
and risk factors of ventilator-associated pneumonia in a Riyadh
hospital. Infect Control Hosp Epidemiol 2000;21(4):271—3.
21. Memish ZA, Oni GA, Djazmati W, Cunningham G, Mah MW. A
randomized clinical trial to compare the effects of a heat and
moisture exchanger with a heated humidifying system on the
occurrence rate of ventilator-associated pneumonia.Am J Infect
Control 2001;29(5):301—5.
22. Simsek S, Yurtseven N, Gercekogalu H, Izgi F, Sohtorik U, Canik S,
et al. Ventilator-associated pneumonias in a cardiothoracic
surgery centre postoperative intensive care unit. J Hosp Infect
2001;47(4):321—4.
23. Jamulitrat S, Narong MN, Thongpiyapoom S. Trauma severity
scoring systems as predictors of nosocomial infection. Infect
Control Hosp Epidemiol 2002;23(5):268—73.
24. Kanafani ZA, Kara L, Hayek S, Kanj SS. Ventilator-associated
pneumonia at a tertiary-care center in a developing country:
incidence, microbiology, and susceptibility patterns of isolated
microorganisms. Infect Control Hosp Epidemiol 2003;24(11):
864—9.
25. Thongpiyapoom S, Narong MN, Suwalak N, Jamulitrat S, Intar-
aksa P, Boonrat J, et al. Device-associated infections and pat-
terns of antimicrobial resistance in a medical-surgical intensivecare unit in a university hospital in Thailand. J Med Assoc Thai
2004;87(7):819—24.
26. Jamulitrat S, Seeluengsawat S, Boonkasame T, Khajorndetchkun
W, Jitsomrouy P, Sathitsupamas T, et al. Stress ulcer prophylaxis
and risk of developing ventilator-associated pneumonia. Am J
Infect Control 2004;32(1):52.
27. Noor A, Hussain SF. Risk factors associated with development of
ventilator associated pneumonia. J Coll Physicians Surg Pak
2005;15(2):92—5.
28. Moreno CA, Rosenthal VD, Olarte N, Gomez WV, Sussmann O,
Agudelo JG, et al. Device-associated infection rate andmortality
in intensive care units of 9 Colombian hospitals: findings of the
International Nosocomial Infection Control Consortium. Infect
Control Hosp Epidemiol 2006;27(4):349—56.
29. Inan D, Saba R, Yalcin AN, Yilmaz M, Ongut G, Ramazanoglu A,
et al. Device-associated nosocomial infection rates in Turkish
medical-surgical intensive care units. Infect Control Hosp Epi-
demiol 2006;27(4):343—8.
30. Ertugrul BM, Yildirim A, Ay P, Oncu S, Cagatay A, Cakar N, et al.
Ventilator-associated pneumonia in surgical emergency inten-
sive care unit. Saudi Med J 2006;27(1):52—7.
31. Ramirez Barba EJ, Rosenthal VD, Higuera F, Oropeza MS, Her-
nandez HT, Lopez MS, et al. Device-associated nosocomial infec-
tion rates in intensive care units in four Mexican public hospitals.
Am J Infect Control 2006;34(4):244—7.
32. Rosenthal VD, Guzman S, Crnich C. Impact of an infection control
program on rates of ventilator-associated pneumonia in inten-
sive care units in 2 Argentinean hospitals. Am J Infect Control
2006;34(2):58—63.
33. Rosenthal VD, Maki DG, Salomao R, Moreno CA, Mehta Y, Higuera
F, et al. Device-associated nosocomial infections in 55 intensive
care units of 8 developing countries. Ann Intern Med
2006;145(8):582—91.
34. Jaimes F, De La Rosa G, Gomez E, Munera P, Ramirez J, Castrillon
S. Incidence and risk factors for ventilator-associated pneumonia
in a developing country: where is the difference? Respir Med
2007;101(4):762—7.
35. Leblebicioglu H, Rosenthal VD, Arikan OA, Ozgultekin A, Yalcin
AN, Koksal I, et al. Device-associated hospital-acquired infection
rates in Turkish intensive care units. Findings of the International
Nosocomial Infection Control Consortium (INICC). J Hosp Infect
2007;65(3):251—7.
36. Sallam SA, Arafa MA, Razek AA, Naga M, Hamid MA. Device-
related nosocomial infection in intensive care units of Alexandria
University Students Hospital. East Mediterr Health J 2005;11(1—
2):52—61.
37. Stebbings AE, Ti TY, Tan WC. Hospital acquired pneumonia in the
medical intensive care unit–—a prospective study. Singapore Med
J 1999;40(8):508—12.
38. Erbay RH, Yalcin AN, Zencir M, Serin S, Atalay H. Costs and risk
factors for ventilator-associated pneumonia in a Turkish univer-
sity hospital’s intensive care unit: a case—control study. BMC
Pulm Med 2004;4:3.
39. Mukhopadhyay C, Bhargava A, Ayyagari A. Role of mechanical
ventilation & development of multidrug-resistant organisms in
hospital-acquired pneumonia. Indian J Med Res 2003;118:
229—35.
40. Namiduru M, Gungor G, Karaoglan I, Dikensoy O. Antibiotic
resistance of bacterial ventilator-associated pneumonia in
surgical intensive care units. J Int Med Res 2004;32(1):
78—83.
41. Pawar M, Mehta Y, Khurana P, Chaudhary A, Kulkarni V, Trehan N.
Ventilator-associated pneumonia: incidence, risk factors, out-
come, andmicrobiology. J Cardiothorac Vasc Anesth 2003;17(1):
22—8.
42. Luna CM, Aruj P, Niederman MS, Garzon J, Violi D, Prignoni A,
et al. Appropriateness and delay to initiate therapy in ventilator-
associated pneumonia. Eur Respir J 2006;27(1):158—64.
512 Y. Arabi et al.43. Wu CL, Yang D, Wang NY, Kuo HT, Chen PZ. Quantitative culture of
endotracheal aspirates in the diagnosis of ventilator-associated
pneumonia in patientswith treatment failure.Chest 2002;122(2):
662—8.
44. Rosenthal VD, Guzman S, Orellano PW. Nosocomial infections in
medical-surgical intensive care units in Argentina: attributable
mortality and length of stay. Am J Infect Control 2003;31(5):
291—5.
45. Berg DE, Hershow RC, Ramirez CA, Weinstein RA. Control of
nosocomial infections in an intensive care unit in Guatemala
City. Clin Infect Dis 1995;21(3):588—93.
46. Khatib M, Jamaleddine G, Abdallah A, Ibrahim Y. Hand washing
and use of gloves while managing patients receiving mechanical
ventilation in the ICU. Chest 1999;116(1):172—5.
47. Salahuddin N, Zafar A, Sukhyani L, Rahim S, Noor MF, Hussain K,
et al. Reducing ventilator-associated pneumonia rates through a
staff education programme. J Hosp Infect 2004;57(3):223—7.
48. Rosenthal VD, Guzman S, Safdar N. Reduction in nosocomial
infection with improved hand hygiene in intensive care units
of a tertiary care hospital in Argentina. Am J Infect Control
2005;33(7):392—7.
49. Danchaivijitr S, Assanasen S, Apisarnthanarak A, Judaeng T,
Pumsuwan V. Effect of an education program on the prevention
of ventilator-associated pneumonia: a multicenter study. J Med
Assoc Thai 2005;88(Suppl 10):S36—41.
50. Arabi Y, Haddad S, Hawes R, Moore T, Pillay M, Naidu B, et al.
Changing sedation practices in the intensive care unit: protocol
implementation, multifaceted multidisciplinary approach and
teamwork. Middle East J Anesthesiol 2007;(19):429—47.51. Raza MW, Kazi BM, Mustafa M, Gould FK. Developing countries
have their own characteristic problems with infection control. J
Hosp Infect 2004;57(4):294—9.
52. CookDJ,Walter SD, CookRJ,Griffith LE,GuyattGH, LeasaD,et al.
Incidence of and risk factors for ventilator-associated pneu-
monia in critically ill patients. Ann Intern Med 1998;129(6):
433—40.
53. Legras A, Malvy D, Quinioux AI, Villers D, Bouachour G, Robert R,
et al. Nosocomial infections: prospective survey of incidence in
five French intensive care units. Intensive Care Med 1998;24(10):
1040—6.
54. Woske HJ, Roding T, Schulz I, Lode H. Ventilator-associated
pneumonia in a surgical intensive care unit: epidemiology, etiol-
ogy and comparison of three bronchoscopic methods for micro-
biological specimen sampling. Crit Care 2001;5(3):167—73.
55. Bouza E, Perez A, Munoz P, Jesus Perez M, Rincon C, Sanchez C,
et al. Ventilator-associated pneumonia after heart surgery: a
prospective analysis and the value of surveillance. Crit Care Med
2003;31(7):1964—70.
56. Urli T, Perone G, Acquarolo A, Zappa S, Antonini B, Ciani A.
Surveillance of infections acquired in intensive care: usefulness
in clinical practice. J Hosp Infect 2002;52(2):130—5.
57. Warren DK, Shukla SJ, Olsen MA, Kollef MH, Hollenbeak CS, Cox
MJ, et al.Outcome and attributable cost of ventilator-associated
pneumonia among intensive care unit patients in a suburban
medical center. Crit Care Med 2003;31(5):1312—7.
58. Kollef MH. Prevention of hospital-associated pneumonia and
ventilator-associated pneumonia. Crit Care Med 2004;32(5):
1396—405.
